Celldex Therapeutics traded at $37.33 this Friday August 12th, increasing $2.80 or 8.11 percent since the previous trading session. Looking back, over the last four weeks, Celldex Therapeutics gained 38.62 percent. Over the last 12 months, its price fell by 14.62 percent. Looking ahead, we forecast Celldex Therapeutics to be priced at 35.67 by the end of this quarter and at 32.79 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
37.33
Daily Change
8.11%
Yearly
-14.62%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 142.60 0.52 0.37% 22.42%
Agenus 2.97 0.30 11.24% -51.71%
Applied Genetic Technologies 0.44 0.01 3.27% -87.64%
Amgen 248.39 0.04 0.02% 8.15%
Aptinyx Inc 0.41 -0.19 -32.33% -83.15%
Biocept 1.17 -0.03 -2.50% -70.75%
Bristol-Myers Squibb 75.57 1.11 1.49% 11.94%
Celldex Therapeutics 37.33 2.80 8.11% -14.62%
CytrRx Corporation 0.11 0.0001 0.09% -85.27%
Glaxosmithkline 36.03 0.30 0.84% -14.15%
Immunogen 5.43 0.19 3.63% 0.93%
Merrimack Pharmaceuticals 4.22 0.02 0.48% -12.81%
Nektar Therapeutics 5.14 0.19 3.84% -64.03%
Lumos Pharma Inc. 8.67 0.36 4.38% 10.78%
Northwest Biotherapeutics 0.63 -0.01 -1.69% -48.15%
Pfizer 50.11 1.82 3.77% 3.36%
Rigel Pharmaceuticals 1.54 0.14 10.00% -58.60%
Roche Holding 315.00 4.85 1.56% -14.39%
Seattle Genetics 170.14 -3.90 -2.24% 8.76%

Indexes Price Day Year
USND 13047 267.27 2.09% -11.98%
US2000 2017 41.36 2.09% -9.29%

Celldex Therapeutics
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutic monoclonal and bispecific antibodies. The Company's drug candidates include antibody-based therapeutics to improve the lives of patients with inflammatory diseases and many forms of cancer. The Company is engaged in the research and development of CDX-015, CDX-1140 and CDX-527. CDX-0159, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, has completed a Phase Ia study in healthy subjects. CDX-1140, an agonist monoclonal antibody targeted to CD40, a key activator of immune response, is being studied in a Phase I study. CDX-527 is the first candidate from Celldex's bispecific antibody platform. CDX-527 is a bispecific antibody that uses the Company's anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway, and Company has initiated a Phase I study in advanced solid tumors.